-Combined company expected to be capitalized with greater than $50 million in cash intended to advance miRagen’s clinical-stage portfolio- BOULDER, Colo. & CARLSBAD, Calif.--(BUSINESS WIRE)--Signal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback